4P Study: Predictive Quality With Painfree Therapies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2011-11-30

Study Completion Date

2016-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the study is to characterize and quantify the relative effectiveness and contribution of implantable cardioverter defibrillator (ICD) therapy to the clinical outcomes under the conditions of daily practice.

Swiss, multicenter, prospective, observational study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Symptoms and Quality of Life in Patients With Implantable Cardiac Defibrillators (ICDs) and Their Caregivers

NCT01454817

Quality of Life Implantable Cardiac Defibrillators ICDs

COMPLETED NA

Deactivation of Implantable Cardioverter Defibrillator During Non-thoracic Surgical Procedures

NCT00806377

Implantable Cardioverter-Defibrillators

COMPLETED

ADVANCE-D: Antitachycardia Pacing (ATP) Delivery for Painless Implantable Cardioverter Defibrillator (ICD) Therapy

NCT00147277

Tachycardia, Ventricular Ventricular Fibrillation

COMPLETED PHASE4

Safety and Clinical Performance of the Protecta ICD and CRT-D

NCT00982397

Tachyarrhythmias Heart Failure Ventricular Dysfunction

COMPLETED NA

Evaluation of the iD-SystemTM, One-Handed Disposable Internal Defibrillation System.

NCT04011631

Ventricular Fibrillation Ventricular Tachycardia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The main role of ICD's is to stop potentially lethal ventricular tachyarrhythmias through overdrive pacing or shock, reducing the risk of sudden cardiac death. The device is programmed to detect episodes of arrhythmias, classify them according to the threat to patient, and deliver therapies to stop the arrhythmias.

The actual focus of ICD programming has been the application of fast-pacing therapies (ATP or antitachy pacing) as first therapy before applying a shock as last resort to terminate an episode. Some studies have shown the high success rate of this method in decreasing the number of shock delivered to patients. Furthermore significant improvement has been done to improve the sensitivity and specificity of the detection and discrimination algorithm.

This study will focus on the latest generation of device and their performance will be reviewed and analyzed by an Adjudication Board.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Arrhythmias

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients having an indication for a Protecta ICD or CRT-D device, or later market released ICD (first implant, replacement, or upgrade)
* Patients monitored with the Carelink monitoring system
* Patients having signed the patient informed consent form
* Patients older than 18 years

Exclusion Criteria

* Patients younger than 18 years of age
* Patients with a life expectancy of less than 24 months
* Females, pregnant and of child bearing potential
* Patients participation to another concomitant trial
* Patients unable or not willing to provide a signed patient informed consent

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No